Genprex Inc. announced that the FDA has granted orphan drug designation to the company's lead drug candidate, Reqorsa immunogene therapy (quaratusugene ozeplasmid, GPX-001), for the treatment of small cell lung cancer (SCLC). Reqorsa contains a plasmid that expresses the tumor suppressor gene TUSC2, the expression of which is reduced or not present in SCLC.
In a study reported in the online edition of Science on Aug. 10, 2023, a group of synthetic biologists from the University of California (UC) San Diego and clinicians from Australia have engineered synthetic bacteria to detect specific DNA sequences in the genomes of colorectal cancer (CRC) cells and organoids. This living cell sensor capable of detecting cancer in the colons of mice has the potential to steer the way to new biosensors capable of identifying various infections, cancers and other diseases.
The composition of the skull bone is unique and plays a direct role in influencing brain health through small channels in the bone and immune cell expression pathways, reported researchers based at the Helmholtz Center and Ludwig-Maximilians University Munich.
Guangzhou Lupeng Pharmaceutical Co. Ltd. and Newave Pharmaceutical LLC have divulged (mutant) ligands reported to be useful for the treatment of cancer, autoimmune disease and inflammation.
Wigen Biomedicine Technology (Shanghai) Co. Ltd. has identified mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1; HPK1; MEKKK1) inhibitors reported to be useful for the treatment of cancer.
Shanghai Lisen Imprinting Pharmaceutical Technology Co. Ltd. has disclosed EGFR (HER1; erbB1) inhibitors reported to be useful for the treatment of small-cell lung (SCLC) and l lung cancer (NSCLC).
Researchers from Acerand Therapeutics (Hong Kong) Ltd. have presented Poly(ADP-ribose) polymerase 1 (PARP-1) inhibitors reported to be useful for the treatment of cancer, metabolic diseases, cardiovascular, inflammatory, psychiatric and immunological disorders.
Researchers from the University of Texas System presented preclinical data for MC-1-F2, a direct small molecule inhibitor of forkhead box protein C2 (FOXC2). The candidate has previously shown activity in breast cancer cell lines, and the current study aimed to assess its efficacy in castration-resistant prostate cancer (CRPC).
Lemonex Inc. announced that the IND application for its mRNA vaccine candidate LEM-mR203 has been approved by the Korean Ministry of Food and Drug Safety (MFDS) on July 21, 2023. The company plans to evaluate LEM-mR203 as potential treatment for COVID-19, with the planned phase I clinical trial being designed to assess its safety and immunogenicity in healthy adults at Seoul National University Hospital, Korea.
RSS
